Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences 03 September
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia 30 August
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress 24 August
